Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trialFei Ma, Binghe Xu, Zhongsheng Tong et al.|BMJ|2023Cited by 82
Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLCLi Jiang, Yongsheng Wang|Scientific Reports|2019Cited by 45
The PI3K/Akt/mTOR Pathway: Immuno-Metabolic Orchestration in IR/MASH-Associated Hepatocellular CarcinomaJian Zhao, Yongsheng Wang, Zhigong Wei et al.|International Journal of Biological Sciences|2025Cited by 12